«After the neurobiological studies pointed out the important role of the GABAB receptor in nicotine reward, and we had positive data in a variety of
animal models of nicotine
dependence, it was time to focus our efforts
on discovery of new molecules that could become therapeutics to assist people to quit smoking.»
Subsequently, work in the Markou laboratory showed that these compounds had desirable effects
on nicotine
dependence in
animal models, while offering a better side - effect profile than other alternatives under study (full agonists at the same receptors).